Association Between Statins Use and Major Bleeding in Patients Using Direct Oral Anticoagulants for Atrial Fibrillation
Pharmacoepidemiology and Drug Safety · 2025
DOI: 10.1002/pds.70245 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2025. Verfasst von A de Burgos-González und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacoepidemiology and Pharmacovigilance, Spanish Agency for Medicines and Medical Devices (AEMPS), Madrid, Spain. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Atrial Fibrillation, Hemorrhage, Anticoagulants. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Tender Proyectos de Investigación en Salud, 2017, Acción Estratégica de Salud, Spanish Agency on Medicines and Medical Devices (AEMPS), Agencia Española de Medicamentos y Productos Sanitarios.
Abstract (Originalsprache)
Background
Direct oral anticoagulants (DOAC) were developed as an alternative to vitamin K antagonists in the treatment of NVAF. Statins are frequently prescribed drugs for the prevention of atherosclerotic cardiovascular disease. A potential interaction between DOACs and statins has been described, suggesting that their concomitant use may increase the risk of major bleeding (MB).
Purpose
To estimate the risk of MB associated with concomitant use of DOACs and statins to assess potential safety issues.
Methods
A case–control study nested in a cohort of new users of DOACs was performed in BIFAP. Cases were defined as MB events and matched to four controls by risk‐set sampling. Treatment episodes were built to define the participants' exposure according to their use at index date as current, recent, past, or no use. Exposure was also assessed in relation to its continuity and duration. Variables were created based on the concomitant use of DOACs and statins to study the interaction, using conditional logistic regression to estimate the risk of MB. Results aOR (95% CI) for current use of DOAC or statin use were 1.35 (0.96–1.9) and 0.72 (0.59–0.88). aOR for their concomitant use was 1.31 (0.83–2.07) compared to nonuse of either of them. DOAC continuous use (1.27; 0.8–2.03) and long‐term (1.11; 0.67–1.81) treatment was associated with smaller risks than noncontinuous (1.40; 0.85–2.32) and short‐term treatment (1.43; 0.94–2.45). Analyses by individual DOACs and statins showed similar results except for edoxaban, which had low numbers.
Conclusions
There was no evidence to suggest an interaction between DOACs and statins and the risk of MB. Regular use of DOACs is important to minimize their impact on MB onset.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pharmacoepidemiology and Pharmacovigilance, Spanish Agency for Medicines and Medical Devices (AEMPS), Madrid, Spain.
- Department of Public Health and Maternal Child Health, Faculty of Medicine, Complutense University of Madrid, Madrid, Spain.
ORCID-Profile: L Cea-Soriano
Förderung
- National Tender Proyectos de Investigación en Salud, 2017, Acción Estratégica de Salud
- Spanish Agency on Medicines and Medical Devices (AEMPS)
- Agencia Española de Medicamentos y Productos Sanitarios
Zitieren
APA
de Burgos-González, A., Cea-Soriano, L., & Huerta-Álvarez, C. (2025). Association Between Statins Use and Major Bleeding in Patients Using Direct Oral Anticoagulants for Atrial Fibrillation. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70245
Vancouver
de Burgos-González A, Cea-Soriano L, Huerta-Álvarez C. Association Between Statins Use and Major Bleeding in Patients Using Direct Oral Anticoagulants for Atrial Fibrillation. Pharmacoepidemiology and Drug Safety. 2025. doi:10.1002/pds.70245
BibTeX
@article{deBurgosGonzlez2025,
author = {de Burgos-González, A and Cea-Soriano, L and Huerta-Álvarez, C},
title = {Association Between Statins Use and Major Bleeding in Patients Using Direct Oral Anticoagulants for Atrial Fibrillation},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2025},
doi = {10.1002/pds.70245}
}
EUVIMED